Cernostics Inc — Department of Health and Human Services SBIR Phase II: 102

Description

DESCRIPTION provided by applicant Barrettandapos s esophagus is a pre neoplastic disease that predisposes patients to development of esophageal adenocarcinoma EAC Approximately million people in the US have Barrettandapos s esophagus and they are frequently screened by endoscopy with pathological analyses of esophageal biopsies The goal of the screening is to detect premalignant changes early to enable interventions to prevent EAC However the pathology analyses are subjective and prone to variation and cannot predict which patients will develop EAC There is an unmet need for accurate prognostic tests to identify high risk patients who require therapeutic interventions to prevent EAC and to identify low risk patients who may be spared unnecessary costly therapy and surveillance Such tests are key to reducing EAC incidence and improving the efficiency of health care spending in this disease area The broad objective of the proposed Phase II study is to validate a prognostic test termed TissueCypher which predicts future risk of developing high grade dysplasia HGD and EAC in patients with Barrettandapos s esophagus The technological innovation of the proposed study is Cernosticsandapos TissueCypher technology a systems biology based approach to anatomic pathology The technology employs multiplexed fluorescence labeling of key tissue system biomarkers including malignant immune and stromal processes in tissue specimens with whole slide fluorescence imaging and image analysis to quantify biomarkers in the context of tissue morphology This is coupled to multivariate classifiers to integrate biomarker data with clinical variables to produce diagnostic prognostic and predictive scores The technical and scientific merit and feasibility of the TissueCypher technology has been demonstrated in Phase I stage type of research through other funding sources Preliminary studies have evaluated biomarkers and morphology in a multi institution cohort of patients with Barrettandapos s esophagus An optimal set of biomarkers image analysis measurements derived from the biomarkers and morphology and a multivariate classifier have been selected which form the basis of the TissueCypher Barrettandapos s risk assessment test that will be validated in the Phase II study The specific aims of the Phase II study are to develop the final format of the TissueCypher test and perform the analytical and clinical performance studies that are required for commercialization The consortium of investigators at Cernostics University of Pittsburgh and Cleveland Clinic will reconfigure the test format and perform analytical and independent clinical validation studies on the TissueCypher test towards the goal of offering the test as a laboratory developed test LDT via a CLIA certified lab The test will be offered as a service to gastroenterologists and pathologists to enable accurate individualized risk stratification for Barrettandapos s patients to improe disease management and reduce the incidence of EAC PUBLIC HEALTH RELEVANCE There is an unmet need for prognostic tests to predict which patients with Barrettandapos s esophagus will progress to esophageal cancer so that screening and preventative treatments can be targeted to the high risk patients Preliminary studies have developed a prognostic test for Barrettandapos s esophagus called TissueCypher and the proposed research aims to further develop and clinically validate this test to enable future commercialization and clinical translation The TissueCypher test will measure an optimal combination of key tissue processes within biopsies including the immune system to accurately stratify patients according to risk of developing esophageal cancer which will improve management of Barrettandapos s esophagus and reduce the incidence of esophageal cancer